Last reviewed · How we verify
Gonadotropin Releasing Hormone Antagonists Relugolix
Gonadotropin Releasing Hormone Antagonists Relugolix is a Small molecule drug developed by Oregon Health and Science University. It is currently FDA-approved.
At a glance
| Generic name | Gonadotropin Releasing Hormone Antagonists Relugolix |
|---|---|
| Sponsor | Oregon Health and Science University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial (PHASE2)
- Supraphysiologic Testosterone Priming Induces Darolutamide Extended Response (PHASE2)
- NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer. (PHASE1)
- Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer (PHASE1, PHASE2)
- Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer (PHASE2)
- Comeback From Long coursE Androgen Deprivation Therapy (ADT) With RElugolix and Darolutamide (CLEARED) (PHASE2)
- Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT (PHASE2)
- Relugolix + Enzalutamide Study in High-Risk Prostate Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Gonadotropin Releasing Hormone Antagonists Relugolix CI brief — competitive landscape report
- Gonadotropin Releasing Hormone Antagonists Relugolix updates RSS · CI watch RSS
- Oregon Health and Science University portfolio CI
Frequently asked questions about Gonadotropin Releasing Hormone Antagonists Relugolix
What is Gonadotropin Releasing Hormone Antagonists Relugolix?
Gonadotropin Releasing Hormone Antagonists Relugolix is a Small molecule drug developed by Oregon Health and Science University.
Who makes Gonadotropin Releasing Hormone Antagonists Relugolix?
Gonadotropin Releasing Hormone Antagonists Relugolix is developed and marketed by Oregon Health and Science University (see full Oregon Health and Science University pipeline at /company/oregon-health-and-science-university).
What development phase is Gonadotropin Releasing Hormone Antagonists Relugolix in?
Gonadotropin Releasing Hormone Antagonists Relugolix is FDA-approved (marketed).